OraSure Technologies Appoints Healthcare Tech Veteran to Board

Company also proposes declassifying board at 2026 annual meeting

Apr. 17, 2026 at 12:10am

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a polished, geometric medical diagnostic device made of brushed metal and glass, floating elegantly on a clean, monochromatic background and backlit to create dramatic shadows, conceptually representing the transformative power of AI-enabled diagnostics in healthcare.A sleek, AI-powered diagnostic device symbolizes OraSure's strategic focus on leveraging cutting-edge technology to advance its healthcare solutions.Bethlehem Today

OraSure Technologies, a leader in diagnostic tests and sample management solutions, announced the appointment of John D. Bertrand to its Board of Directors as an independent director. Bertrand is a healthcare technology executive with over a decade of experience driving AI-enabled innovation in diagnostics. The company also said it will seek shareholder approval at its 2026 Annual Meeting to declassify the Board, further strengthening its commitment to strong governance and shareholder engagement.

Why it matters

OraSure's move to add Bertrand to its board and declassify the board structure signals the company's focus on accelerating growth and improving margins through strategic initiatives, including leveraging AI and digital health technologies. This aligns with the company's multi-year transformation strategy and comes amid constructive engagement with investor Altai Capital.

The details

Bertrand co-founded Digital Diagnostics Inc. and most recently served as its CEO, helping transform the company from a research-stage organization into a global commercial platform for disease diagnosis. Previously, he held senior leadership roles at Epic Systems Corporation. OraSure also announced it will seek shareholder approval at its 2026 Annual Meeting to declassify the Board, further underscoring its commitment to strong governance and ongoing shareholder engagement.

  • OraSure announced Bertrand's appointment effective immediately.
  • The company will seek shareholder approval to declassify the Board at its 2026 Annual Meeting.

The players

John D. Bertrand

A healthcare technology executive with over a decade of experience driving AI-enabled innovation in diagnostics. He co-founded Digital Diagnostics Inc. and most recently served as its CEO.

OraSure Technologies, Inc.

A leader in point-of-need and home diagnostic tests and sample management solutions, transforming health through actionable insight and decentralizing diagnostics.

Altai Capital Management, L.P.

An investment management firm that engaged constructively with OraSure and is withdrawing its director nominations for the 2026 Annual Meeting.

Got photos? Submit your photos here. ›

What they’re saying

“We are pleased to welcome John to our Board as we continue to make meaningful progress in advancing our multi-year transformation strategy. OraSure is well positioned to continue accelerating our growth and driving margin improvement, and we believe John's experience in AI-enabled diagnostics and commercial healthcare technology will strengthen our strategic efforts.”

— Jack Kenny, Chair of the OTI Board

“We are pleased with the outcome of our engagement with OraSure and the steps the Company has taken to enhance its Board and governance practices. John's appointment, together with our ongoing constructive dialogue with OraSure's Board and management team, strengthens our confidence that the Company is on the path to delivering sustained value.”

— Rishi Bajaj, Founder and CIO of Altai

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

OraSure's move to add a healthcare technology veteran to its board and declassify the board structure signals the company's focus on leveraging AI and digital health to accelerate growth and improve margins, aligning with its multi-year transformation strategy and constructive engagement with an investor.